ZNF37A

Summary

ZNF37A (zinc finger protein 37A, HGNC:13102) is a protein-coding gene on chromosome 10p11.1, encoding Zinc finger protein 37A (P17032). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Located in nucleus.

Source: NCBI Gene 7587 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_001324250

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13102
Approved symbol	ZNF37A
Name	zinc finger protein 37A
Location	10p11.1
Locus type	gene with protein product
Status	Approved
Aliases	KOX21, ZNF37
Ensembl gene	ENSG00000075407
Ensembl biotype	protein_coding
OMIM	616085
Entrez	7587

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 24 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000351773, ENST00000361085, ENST00000477790, ENST00000479469, ENST00000498773, ENST00000638053, ENST00000685332, ENST00000865425, ENST00000865426, ENST00000865427, ENST00000865428, ENST00000865429, ENST00000865430, ENST00000865431, ENST00000865432, ENST00000865433, ENST00000865434, ENST00000865436, ENST00000865437, ENST00000865438, ENST00000865439, ENST00000865440, ENST00000865441, ENST00000950340, ENST00000950341, ENST00000950342, ENST00000950343

RefSeq mRNA: 20 — MANE Select: NM_001324250 NM_001007094, NM_001178101, NM_001324245, NM_001324246, NM_001324247, NM_001324248, NM_001324249, NM_001324250, NM_001324251, NM_001324252, NM_001324253, NM_001324254, NM_001324256, NM_001324257, NM_001324258, NM_001324259, NM_001324260, NM_001324261, NM_001324262, NM_003421

CCDS: CCDS31183, CCDS81451

Canonical transcript exons

ENST00000685332 — 8 exons

Exon	Start	End
ENSE00001393757	38094931	38095224
ENSE00001394471	38095744	38095804
ENSE00002486554	38115195	38115290
ENSE00003493708	38096574	38096632
ENSE00003510613	38114755	38114881
ENSE00003799541	38095538	38095629
ENSE00003925003	38117390	38124625
ENSE00003930768	38094337	38094490

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 96.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6279 / max 95.3759, expressed in 1657 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104722	8.6279	1657

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	96.24	gold quality
visceral pleura	UBERON:0002401	95.34	gold quality
parietal pleura	UBERON:0002400	94.32	gold quality
tibia	UBERON:0000979	94.15	gold quality
pleura	UBERON:0000977	93.11	gold quality
buccal mucosa cell	CL:0002336	91.23	gold quality
tendon of biceps brachii	UBERON:0008188	90.27	gold quality
seminal vesicle	UBERON:0000998	90.19	gold quality
decidua	UBERON:0002450	89.20	gold quality
primary visual cortex	UBERON:0002436	88.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	88.13	gold quality
tendon	UBERON:0000043	87.67	gold quality
cerebellar vermis	UBERON:0004720	87.56	gold quality
postcentral gyrus	UBERON:0002581	87.03	gold quality
calcaneal tendon	UBERON:0003701	86.88	gold quality
colonic epithelium	UBERON:0000397	86.29	gold quality
corpus callosum	UBERON:0002336	85.58	gold quality
parietal lobe	UBERON:0001872	85.57	gold quality
sural nerve	UBERON:0015488	85.55	gold quality
medial globus pallidus	UBERON:0002477	85.52	gold quality
entorhinal cortex	UBERON:0002728	85.31	gold quality
occipital lobe	UBERON:0002021	85.24	gold quality
cerebellar cortex	UBERON:0002129	84.96	gold quality
cerebellar hemisphere	UBERON:0002245	84.92	gold quality
globus pallidus	UBERON:0001875	84.61	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.52	gold quality
germinal epithelium of ovary	UBERON:0001304	84.27	gold quality
cerebellum	UBERON:0002037	84.00	gold quality
superior frontal gyrus	UBERON:0002661	83.90	gold quality
pituitary gland	UBERON:0000007	83.89	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

122 targeting ZNF37A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909

Literature-anchored findings (GeneRIF, showing 2)

• This suggests that the pathological molecular mechanisms linking ZNF37A and myogenesis may involve the signaling pathway that is known to promote myoblast recruitment during development and regeneration (PMID:23922231)
• ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-beta axis in colorectal cancer. (PMID:33875786)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

Zinc finger protein 37A — P17032 (reviewed: P17032)

Alternative names: Zinc finger protein KOX21

All UniProt accessions (2): P17032, A0A1B0GVV4

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Induction. Down-regulated in cells with DM1 (Myotonic dystrophy type 1) mutation, via a mechanism that involves abnormal control of its mRNA stability by CUGBP1.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (20): NP_001007095, NP_001171572, NP_001311174, NP_001311175, NP_001311176, NP_001311177, NP_001311178, NP_001311179, NP_001311180, NP_001311181, NP_001311182, NP_001311183, NP_001311185, NP_001311186, NP_001311187, NP_001311188, NP_001311189, NP_001311190, NP_001311191, NP_003412 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (15 total): zinc finger region 12, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P17032-F1	64.29	0.22

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 99 (showing top): BROWNE_HCMV_INFECTION_16HR_UP, BROWNE_HCMV_INFECTION_12HR_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, chr10p11, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, ZWANG_DOWN_BY_2ND_EGF_PULSE, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ARID5B_TARGET_GENES, E2F5_TARGET_GENES, KAT2A_TARGET_GENES, KAT5_TARGET_GENES, SALL4_TARGET_GENES, ZBTB18_TARGET_GENES, ZNF331_TARGET_GENES

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription by RNA polymerase II	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

592 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF37A	PLCB4	Q15147	429
ZNF37A	C18orf32	Q8TCD1	336
ZNF37A	MOGAT3	Q86VF5	322
ZNF37A	MTRNR2L7	P0CJ74	308
ZNF37A	ZNF518A	Q6AHZ1	305
ZNF37A	KNOP1	Q1ED39	290
ZNF37A	TBC1D2B	Q9UPU7	266
ZNF37A	GPATCH3	Q96I76	265
ZNF37A	BANP	Q8N9N5	264
ZNF37A	ASAP3	Q8TDY4	261
ZNF37A	SLC25A1	P53007	249
ZNF37A	YPEL1	O60688	248
ZNF37A	CELA2B	P08218	248
ZNF37A	PIGW	Q7Z7B1	247
ZNF37A	NSRP1	Q9H0G5	245

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF37A	H1-2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (6): ZNF37A (Proximity Label-MS), ZNF37A (Negative Genetic), ZNF37A (Affinity Capture-MS), ZNF37A (Affinity Capture-MS), ZNF37A (Affinity Capture-RNA), ZNF37A (Proximity Label-MS)

ESM2 similar proteins: A2VDP4, A6NHJ4, O94892, P0CJ79, P17014, P17021, P17025, P17032, P17035, P18733, P51508, P51814, Q06730, Q06732, Q09FC8, Q0VGE8, Q14586, Q32M78, Q3MIS6, Q5JVG2, Q5R4K8, Q5R9S5, Q5RBQ3, Q5RCJ2, Q5RER9, Q5TYW1, Q5VIY5, Q6P560, Q6PDB4, Q6ZMW2, Q6ZN06, Q6ZNA1, Q76KX8, Q7L2R6, Q86Y25, Q8N184, Q8N823, Q8N883, Q8N8J6, Q8NEP9

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	80
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1184 predictions. Top by Δscore:

Variant	Effect	Δscore
10:38095630:GTCT:G	donor_gain	1.0000
10:38095742:A:AG	acceptor_gain	1.0000
10:38095743:G:GG	acceptor_gain	1.0000
10:38095743:GA:G	acceptor_gain	1.0000
10:38095800:ACAGA:A	donor_gain	1.0000
10:38095801:CAGA:C	donor_gain	1.0000
10:38095803:GA:G	donor_gain	1.0000
10:38095803:GAGTA:G	donor_loss	1.0000
10:38095805:G:GG	donor_gain	1.0000
10:38095805:GTAA:G	donor_loss	1.0000
10:38096565:A:AG	acceptor_gain	1.0000
10:38096566:T:G	acceptor_gain	1.0000
10:38096569:CTCA:C	acceptor_loss	1.0000
10:38096570:TCA:T	acceptor_loss	1.0000
10:38096572:A:AG	acceptor_gain	1.0000
10:38096573:G:GA	acceptor_gain	1.0000
10:38096573:GC:G	acceptor_gain	1.0000
10:38096573:GCT:G	acceptor_gain	1.0000
10:38096573:GCTA:G	acceptor_gain	1.0000
10:38096573:GCTAC:G	acceptor_gain	1.0000
10:38096628:CCCAG:C	donor_gain	1.0000
10:38096629:CCAG:C	donor_gain	1.0000
10:38096630:CAG:C	donor_gain	1.0000
10:38096630:CAGG:C	donor_loss	1.0000
10:38096631:AG:A	donor_gain	1.0000
10:38096632:GG:G	donor_gain	1.0000
10:38096633:G:GG	donor_gain	1.0000
10:38096633:GTAA:G	donor_loss	1.0000
10:38114878:GTAG:G	donor_gain	1.0000
10:38115193:AG:A	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000040282 (10:38098503 A>C), RS1000187954 (10:38121512 A>G), RS1000235619 (10:38125047 C>T), RS1000406570 (10:38118683 T>C), RS1000508440 (10:38138946 A>T), RS1000700410 (10:38131564 T>C), RS1000889491 (10:38113031 C>T), RS1000921290 (10:38094388 T>C), RS1000922072 (10:38113317 A>G), RS1001049868 (10:38145370 A>G), RS1001062916 (10:38145673 T>C), RS1001221117 (10:38117673 C>A), RS1001369120 (10:38104270 C>A,T), RS1001533824 (10:38131164 T>C), RS1001551288 (10:38106210 G>T)

Disease associations

OMIM: gene MIM:616085 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010919_4	QT interval	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
dimethylselenide	increases oxidation, decreases expression, increases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
ferrous chloride	decreases expression	1
cupric oxide	increases expression	1
epigallocatechin gallate	increases expression, affects cotreatment	1
avobenzone	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	decreases expression	1
K 7174	increases expression	1
abrine	decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Aspirin	increases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	increases expression	1
Cisplatin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Glucose	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome